Cell cycle inhibitor p21/WAF1/CIP1 as a cofactor of MITF expression in melanoma cells

Pigment Cell and Melanoma Research

Volumn 23, Issue 2, 2010, Pages 238-251

  Šestáková, Blanka ^a   Ondrušová, Lubica ^a   Vachtenheim, Jiri ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CREB; Melanoma; MITF; p21; WAF1

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PROTEIN P21; SHORT HAIRPIN RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOCYTE; MELANOMA CELL; NONHUMAN; POSITIVE FEEDBACK; PROMOTER REGION; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77949389035     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00670.x     Document Type: Article

References (52)

1. Abbas, T., and Dutta, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400-414.
2. Alonso, S.R., Ortiz, P., Pollan, M. et al. (2004). Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 164, 193-203.
3. Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K., and Mizutani, S. (1999). Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18, 1223-1234.
4. Bertolotto, C., Abbe, P., Hemesath, T.J., Bille, K., Fisher, D.E., Ortonne, J.P., and Ballotti, R. (1998). Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell Biol. 142, 827-835.
5. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L., and Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769.
6. Coqueret, O., and Gascan, H. (2000). Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J. Biol. Chem. 275, 18794-18800.
7. Cronin, J.C., Wunderlich, J., Loftus, S.K. et al. (2009). Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 22, 435-444.
8. Delavaine, L., and La Thangue, N.B. (1999). Control of E2F activity by p21Waf1/Cip1. Oncogene 18, 5381-5392.
9. Devgan, V., Mammucari, C., Millar, S.E., Brisken, C., and Dotto, G.P. (2005). p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 19, 1485-1495.
10. Dobroff, A.S., Wang, H., Melnikova, V.O., Villares, G.J., Zigler, M., Huang, L., and Bar-Eli, M. (2009). Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J. Biol. Chem. 284, 26194-26206.
11. Dotto, G.P. (2000). p21(WAF1/Cip1): more than a break to the cell cycle? Biochim. Biophys. Acta 1471, M43-M56.
12. Drdova, B., and Vachtenheim, J. (2004). Repression of the melanocyte-specific promoter of the microphthalmia-associated transcription factor by the adenoviral E1A 12S oncoprotein. Folia Biol. (Praha) 50, 159-166.
13. Drdova, B., and Vachtenheim, J. (2005). A role for p21 (WAF1) in the cAMP-dependent differentiation of F9 teratocarcinoma cells into parietal endoderm. Exp. Cell Res. 304, 293-304.
14. Du, J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Ross, K., Huber, W.E., Nishimura, E.K., Golub, T.R., and Fisher, D.E. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576.
15. Dynek, J.N., Chan, S.M., Liu, J., Zha, J., Fairbrother, W.J., and Vucic, D. (2008). Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 68, 3124-3132.
16. Fritah, A., Saucier, C., Mester, J., Redeuilh, G., and Sabbah, M. (2005). p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol. Cell Biol. 25, 2419-2430.
17. Garcia-Wilson, E., and Perkins, N.D. (2005). p21WAF1/CIP1 regulates the p300 sumoylation motif CRD1 through a C-terminal domain independently of cyclin/CDK binding. Cell Cycle 4, 1113-1119.
18. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
19. Girdwood, D., Bumpass, D., Vaughan, O.A., Thain, A., Anderson, L.A., Snowden, A.W., Garcia-Wilson, E., Perkins, N.D., and Hay, R.T. (2003). P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11, 1043-1054.
20. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M.C., and Holbrook, N.J. (1997). p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14, 929-935.
21. Gregory, D.J., Garcia-Wilson, E., Poole, J.C., Snowden, A.W., Roninson, I.B., and Perkins, N.D. (2002). Induction of transcription through the p300 CRD1 motif by p21WAF1/CIP1 is core promoter specific and cyclin dependent kinase independent. Cell Cycle 1, 343-350.
22. Halaban, R., Cheng, E., Zhang, Y., Mandigo, C.E., and Miglarese, M.R. (1998). Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene 16, 2489-2501.
23. Janicke, R.U., Sohn, D., Essmann, F., and Schulze-Osthoff, K. (2007). The multiple battles fought by anti-apoptotic p21. Cell Cycle 6, 407-413.
24. Jean, D., Harbison, M., McConkey, D.J., Ronai, Z., and Bar-Eli, M. (1998). CREB and its associated proteins act as survival factors for human melanoma cells. J. Biol. Chem. 273, 24884-24890.
25. Johannessen, M., Delghandi, M.P., and Moens, U. (2004). What turns CREB on? Cell. Signal. 16, 1211-1227.
26. Karjalainen, J.M., Eskelinen, M.J., Kellokoski, J.K., Reinikainen, M., Alhava, E.M., and Kosma, V.M. (1999). p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br. J. Cancer 79, 895-902.
27. Kawata, S., Ariumi, Y., and Shimotohno, K. (2003). p21(Waf1/Cip1/Sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded tax. J. Virol. 77, 7291-7299.
28. Kitaura, H., Shinshi, M., Uchikoshi, Y., Ono, T., Iguchi-Ariga, S.M., and Ariga, H. (2000). Reciprocal regulation via protein-protein interaction between c-Myc and p21(cip1/waf1/sdi1) in DNA replication and transcription. J. Biol. Chem. 275, 10477-10483.
29. Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414.
30. Lohr, K., Moritz, C., Contente, A., and Dobbelstein, M. (2003). p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278, 32507-32516.
31. Maelandsmo, G.M., Holm, R., Fodstad, O., Kerbel, R.S., and Florenes, V.A. (1996). Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am. J. Pathol. 149, 1813-1822.
32. Miyagishi, M., Fujii, R., Hatta, M., Yoshida, E., Araya, N., Nagafuchi, A., Ishihara, S., Nakajima, T., and Fukamizu, A. (2000). Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300. J. Biol. Chem. 275, 35170-35175.
33. Perkins, N.D., Felzien, L.K., Betts, J.C., Leung, K., Beach, D.H., and Nabel, G.J. (1997). Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523-527.
34. Poole, J.C., Thain, A., Perkins, N.D., and Roninson, I.B. (2004). Induction of transcription by p21Waf1/Cip1/Sdi1: role of NFkappaB and effect of non-steroidal anti-inflammatory drugs. Cell Cycle 3, 931-940.
35. Poyraz, A., Akyurek, N., Gonul, I.I., and Erdem, O. (2004). P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters. J. Exp. Clin. Cancer Res. 23, 625-631.
36. Redeuilh, G., Attia, A., Mester, J., and Sabbah, M. (2002). Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases. Oncogene 21, 5773-5782.
37. Sato, S., Roberts, K., Gambino, G., Cook, A., Kouzarides, T., and Goding, C.R. (1997). CBP/p300 as a co-factor for the microphthalmia transcription factor. Oncogene 14, 3083-3092.
38. delaSerna, B.C., Fugimori, M.L., Ribeiro, K.C., Duprat Neto, J.P., Neves, R.I., and Landman, G. (2009). Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. Melanoma Res. 19, 135-141.
39. Sherr, C.J., and Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
40. Snowden, A.W., Anderson, L.A., Webster, G.A., and Perkins, N.D. (2000). A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol. Cell Biol. 20, 2676-2686.
41. Sparrow, L.E., Eldon, M.J., English, D.R., and Heenan, P.J. (1998). p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. J. Dermatopathol. 20, 255-261.
42. Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T., and Miura, M. (1998). Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17, 931-939.
43. Trotter, M.J., Tang, L., and Tron, V.A. (1997). Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J. Cutan. Pathol. 24, 265-271.
44. Vachtenheim, J., Novotna, H., and Ghanem, G. (2001). Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J. Invest Dermatol. 117, 1505-1511.
45. Vachtenheim, J., Sestakova, B., and Tuhackova, Z. (2007). Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators. Pigment Cell Res. 20, 41-51.
46. Vidal, M.J., Loganzo, F. Jr, de Oliveira, A.R., Hayward, N.K., and Albino, A.P. (1995). Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 5, 243-250.
47. Vigneron, A., Cherier, J., Barre, B., Gamelin, E., and Coqueret, O. (2006). The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J. Biol. Chem. 281, 34742-34750.
48. Wang, J., Devgan, V., Corrado, M., Prabhu, N.S., El Deiry, W.S., Riccardi, C., Pandolfi, P.P., Missero, C., and Dotto, G.P. (2005). Glucocorticoid-induced tumor necrosis factor receptor is a p21Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. J. Biol. Chem. 280, 37725-37731.
49. Weiss, R.H. (2003). p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4, 425-429.
50. Wiznerowicz, M., and Trono, D. (2003). Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77, 8957-8961.
51. Wohlschlegel, J.A., Dwyer, B.T., Takeda, D.Y., and Dutta, A. (2001). Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Mol. Cell Biol. 21, 4868-4874.
52. Xie, S., Price, J.E., Luca, M., Jean, D., Ronai, Z., and Bar-Eli, M. (1997). Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15, 2069-2075.